Enanta Pharmaceuticals | Devedores Comerciais





Devedores Comerciais Alterar Data
AbbVie USD 12.77B 132M 2025-09
Amgen USD 9.57B 1.08B 2025-12
Anika Therapeutics USD 21.99M 1.61M 2025-03
Arrowhead Research USD 218.87M 212.05M 2025-12
AstraZeneca USD 19.05B 1.49B 2025-12
BioCryst Pharmaceuticals USD 79.07M 6.61M 2024-12
Biogen USD 1.85B 234M 2025-09
Bristol-Myers Squibb USD 14.62B 485M 2025-09
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Gilead Sciences USD 4.91B 182M 2025-12
GlaxoSmithKline GBP 7.76B 545M 2025-12
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
Heron Therapeutics USD 67.04M 6.9M 2024-09
Immunic USD 1.5M 50K 2024-06
Incyte USD 1.02B 128.52M 2025-12
Insmed USD 140.86M 75.6M 2025-12
Ionis Pharmaceuticals USD 66M 41.39M 2025-12
J&J USD 17.61B 235M 2025-09
Karyopharm Therapeutics USD 31.78M 6.82M 2024-09
Ligand Pharmaceuticals USD 58.1M 15.98M 2025-09
Merck USD 12.12B 596M 2025-09
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Novartis USD 8.98B 192M 2025-09
Novavax USD 94.96M 62.81M 2024-09
Pfizer USD 18.12B 2.02B 2025-09
PTC Therapeutics USD 181.62M 21.45M 2025-12
Roche Holding CHF 11.9B 460M 2025-12
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Vertex Pharmaceuticals USD 2.05B 106.4M 2025-12


Enanta Pharmaceuticals Devedores Comerciais - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Mar 2026.